npj Breast Cancer (Apr 2025)
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
- Rodrigo Sánchez-Bayona,
- Olga Martínez-Sáez,
- Denys Romero-Romero,
- Elia Seguí,
- Esther Carcelero,
- Pablo Tolosa,
- Jesús Soberino,
- Manuel Alva,
- Tomás Pascual,
- Laura Lema,
- Isabel Garcia-Fructuoso,
- Maria Angeles Cobos-Fernandez,
- Maria Rey,
- Luis Manso,
- Angela Aguirre,
- Ainhoa Madariaga,
- Valeria Sirenko,
- Cristina González-Deza,
- Paula Blasco,
- Astrid Mayhua,
- Oleguer Castillo,
- Patricia Galván,
- Esther Sanfeliu,
- Guillermo Villacampa,
- Wesley Buckingham,
- Mercedes Marín-Aguilera,
- Laia Paré,
- Patricia Villagrasa,
- Charles M. Perou,
- Julia Maues,
- Fara Brasó-Maristany,
- Eva Ciruelos,
- Aleix Prat
Affiliations
- Rodrigo Sánchez-Bayona
- Hospital Universitario 12 de Octubre
- Olga Martínez-Sáez
- SOLTI Breast Cancer Research Group
- Denys Romero-Romero
- Hospital Universitario 12 de Octubre
- Elia Seguí
- SOLTI Breast Cancer Research Group
- Esther Carcelero
- Pharmacy Department, Hospital Clinic
- Pablo Tolosa
- Hospital Universitario 12 de Octubre
- Jesús Soberino
- Breast Cancer Unit, IOB-QuirónSalud
- Manuel Alva
- Hospital Universitario 12 de Octubre
- Tomás Pascual
- SOLTI Breast Cancer Research Group
- Laura Lema
- Hospital Universitario 12 de Octubre
- Isabel Garcia-Fructuoso
- SOLTI Breast Cancer Research Group
- Maria Angeles Cobos-Fernandez
- Hospital Universitario 12 de Octubre
- Maria Rey
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Luis Manso
- Hospital Universitario 12 de Octubre
- Angela Aguirre
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Ainhoa Madariaga
- Hospital Universitario 12 de Octubre
- Valeria Sirenko
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Cristina González-Deza
- Hospital Universitario 12 de Octubre
- Paula Blasco
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Astrid Mayhua
- Hospital Universitario 12 de Octubre
- Oleguer Castillo
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Patricia Galván
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Esther Sanfeliu
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Guillermo Villacampa
- SOLTI Breast Cancer Research Group
- Wesley Buckingham
- Reveal Genomics
- Mercedes Marín-Aguilera
- Reveal Genomics
- Laia Paré
- Reveal Genomics
- Patricia Villagrasa
- Reveal Genomics
- Charles M. Perou
- Reveal Genomics
- Julia Maues
- GRASP
- Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- Eva Ciruelos
- Hospital Universitario 12 de Octubre
- Aleix Prat
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)
- DOI
- https://doi.org/10.1038/s41523-025-00753-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 7
Abstract
Abstract In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX ERBB2 mRNA score as a prognostic predictor, aiming to tailor treatment strategies. We retrospectively analyzed 94 patients treated with the THP regimen between 2010 and 2024. The HER2DX ERBB2 mRNA score was categorized as low (n = 14), medium (n = 20), or high (n = 60), and its correlation with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. The median follow-up was 31.5 months. Patients with ERBB2-high scores had significantly better median PFS (33.9 vs. 10.6 months, hazard ratio [HR] = 0.40, 95% CI: 0.24–0.69, p < 0.001) and OS (not reached vs. 30.8 months, HR = 0.26, 95% CI: 0.13–0.49, p < 0.001) compared to ERBB2-low patients. Based on these findings, further validation of this biomarker in tumor samples from the CLEOPATRA phase III trial is ongoing, which could help optimize treatment strategies in this population.
